Literature DB >> 2010681

99mTechnetium-labeled low density lipoprotein: receptor recognition and intracellular sequestration of radiolabel.

A M Lees1, R S Lees.   

Abstract

99MTechnetium-labeled low density lipoprotein (99MTc-labeled LDL) was developed to detect atherosclerosis by external imaging with the gamma scintillation camera (Lees, et al. J. Nucl. Med. 1985. 26: 1056-1062; Lees, et al. Arteriosclerosis. 1988. 8: 461-470). The present study examined high affinity LDL receptor recognition and intracellular sequestration of 99MTc-labeled LDL by fibroblasts. There were no significant differences between 99MTc-labeled LDL and 125I-labeled LDL in binding parameters or percent inhibition of accumulation, which indicated that 99MTc labeling did not alter receptor recognition of LDL. At 4 degrees C the Kd (+SE) for 99MTc-labeled LDL and 125I-labeled LDL, respectively, was 1.52 +/- 0.24 and 1.45 +/- 0.14 micrograms/ml; Bmax (+/- SE) was 5.45 +/- 0.48 and 4.89 +/- 0.25 ng/well, respectively. Binding was saturated at about 2 micrograms/ml. The complete linearity of 99MTc-labeled LDL accumulation from 0-6 h and the positive slope from 6-24 h indicated that radiolabel that entered cells as 99MTc-labeled LDL was sequestered; pulse-chase experiments, which measured residual cell-associated radioactivity out to 24 h, also showed that radiolabel was trapped. Because radiolabel sequestration was essentially complete, and because 99MTc-labeled LDL was recognized by the LDL receptor equally as well as 125I-labeled LDL, it should be useful not only for imaging atherosclerosis, but also for quantitatively determining sites of utilization and degradation of LDL.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2010681

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  6 in total

1.  Progression of detail.

Authors: 
Journal:  J Nucl Cardiol       Date:  2000-03       Impact factor: 5.952

2.  Low-density lipoprotein nanoparticles as magnetic resonance imaging contrast agents.

Authors:  Ian R Corbin; Hui Li; Juan Chen; Sissel Lund-Katz; Rong Zhou; Jerry D Glickson; Gang Zheng
Journal:  Neoplasia       Date:  2006-06       Impact factor: 5.715

3.  Technetium-99m labelled LDL as a tracer for quantitative LDL scintigraphy. I. Tracer purification, in vitro and in vivo long-term stability, in vitro validation and biodistribution.

Authors:  T Leitha; M Hermann; M Hüttinger; P Angelberger; R Dudczak
Journal:  Eur J Nucl Med       Date:  1993-08

4.  Technetium-99m labelled LDL as a tracer for quantitative LDL scintigraphy. II. In vivo validation, LDL receptor-dependent and unspecific hepatic uptake and scintigraphic results.

Authors:  T Leitha; A Staudenherz; B Gmeiner; M Hermann; M Hüttinger; R Dudczak
Journal:  Eur J Nucl Med       Date:  1993-08

Review 5.  Lipoprotein-Related and Apolipoprotein-Mediated Delivery Systems for Drug Targeting and Imaging.

Authors:  Gunter Almer; Harald Mangge; Andreas Zimmer; Ruth Prassl
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

6.  Naphthalocyanine-reconstituted LDL nanoparticles for in vivo cancer imaging and treatment.

Authors:  Liping Song; Hui Li; Ulas Sunar; Juan Chen; Ian Corbin; Arjun G Yodh; Gang Zheng
Journal:  Int J Nanomedicine       Date:  2007
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.